Thu, Oct 2, 2014, 1:41 PM EDT - U.S. Markets close in 2 hrs 19 mins

Recent

% | $
Quotes you view appear here for quick access.

Elan Corporation, plc Message Board

aknb9 1 post  |  Last Activity: Aug 20, 2014 8:43 AM Member since: Feb 23, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Neurotrope's Approach to Treating Alzheimer's Disease Through Its Product Bryostatin-1, an Activator of Protein Kinase C Epsilon (PKCe), Supported by Blanchette Rockefeller Neurosciences Institute (BRNI) Publication, Identifying PKCe as a Biomarker of Alzheimer's
    Neurotrope's Collaborator BRNI, Publishes Article in the Journal of Alzheimer's Disease describing correlation of PKCe levels and degree of disease
    Neurotrope, Inc.
    Aug 18, 2014 9:13 AM

    PLANTATION, Fla., Aug. 18, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB:NTRP) today announced that results from a new study, entitled, "PKCe Deficits in Alzheimer's Disease Brains and Skin Fibroblasts," published in the recent edition of the peer-reviewed Journal of Alzheimer's Disease and co-authored by Tapan K. Khan, Ph.D.; Abhik Sen, Ph.D.; Jarin Hongpaisan, Ph.D.; Chol S. Lim, Ph.D.; Thomas J. Nelson, Ph.D., and; Dr. Daniel L. Alkon, each of the Blanchette Rockefeller Neurosciences Institute (BRNI), provide further indication of the role that protein kinase C epsilon (PKCe) may play in the potential treatment of Alzheimer's disease (AD). Neurotrope is currently collaborating with BRNI on the development of its lead compound, bryostatin, a potent modulator of PKCe, for the treatment of patients with AD.

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.